RVX-208 can rapidly increase plasma levels of ApoA-I up to 150% relative to control in animals in the first 24 hours.
In previously announced studies, Resverlogix stated that RVX-208 substantially increased the plasma levels of ApoA-I up to 180% following seven days treatment. Taken together, the data solidly demonstrates that in animal models RVX-208 rapidly increases the production of ApoA-I and that the large elevations of ApoA-I are sustained over time.
“This observation lends support for an accelerated development path for RVX-208,” stated Dr Jan Johansson, senior vice president of clinical development.
According to the American Heart Association, acute cardiovascular diseases account for more than $142 billion in direct and indirect costs in North America.
“Evidence is mounting that RVX-208 could offer a distinct advantage in the treatment of cardiovascular disease over current technologies such as statins and other lipid regulating drugs that take months to reach full effect,” said Kenneth Lebioda, senior vice president of business & market development.